Search results for "Heterograft"

showing 10 items of 38 documents

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy

2022

Abstract Background Aberrant activation of the MET receptor in cancer is sustained by genetic alterations or, more frequently, by transcriptional upregulations. A fraction of MET-amplified or mutated tumors are sensible to MET targeting agents, but their responsiveness is typically short-lasting, as secondary resistance eventually occurs. Since in the absence of genetic alterations MET is usually not a tumor driver, MET overexpressing tumors are not/poorly responsive to MET targeted therapies. Consequently, the vast majority of tumors exhibiting MET activation still represent an unmet medical need. Methods Here we propose an immunotherapy strategy based on T lymphocytes expressing a Chimeri…

Cancer ResearchReceptors Chimeric AntigenTumorTargeted therapy.T-LymphocytesChimeric AntigenXenograft Model Antitumor AssaysCARCell LineTargeted therapyMiceOncologyCell Line TumorMET oncogeneReceptorsHumansAnimalsHeterograftsImmunotherapyCAR; Gastric cancer; Immunotherapy; MET oncogene; Targeted therapy; Humans; Mice; Animals; Immunotherapy; T-Lymphocytes; Cell Line Tumor; Heterografts; Xenograft Model Antitumor Assays; Receptors Chimeric AntigenGastric cancer
researchProduct

High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients.

2012

International audience; ABSTRACT: INTRODUCTION: The gene quiescin/sulfhydryl oxidase 1, QSOX1, encodes an enzyme directed to the secretory pathway and excreted into the extracellular space. QSOX1 participates in the folding and stability of proteins and thus could regulate the biological activity of its substrates in the secretory pathway and/or outside the cell. The involvement of QSOX1 in oncogenesis has been studied primarily in terms of its differential expression in systemic studies. QSOX1 is overexpressed in prostate cancers and in pancreatic adenocarcinoma. In contrast, QSOX1 gene expression is repressed in endothelial tumors. In the present study, we investigated the role of QSOX1 i…

CellGene ExpressionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologymedicine.disease_causeMetastasis[ SDV.CAN ] Life Sciences [q-bio]/CancerMice03 medical and health sciences0302 clinical medicineBreast cancer[SDV.CAN] Life Sciences [q-bio]/CancerCell MovementCell Line TumormedicineExtracellularAnimalsHumansOxidoreductases Acting on Sulfur Group DonorsRNA MessengerNeoplasm MetastasisCell ProliferationRetrospective Studies030304 developmental biologyMedicine(all)0303 health sciencesCell growthCancermedicine.diseaseExtracellular MatrixTumor Burden3. Good healthPatient Outcome AssessmentDisease Models AnimalProtein TransportCell Transformation Neoplasticmedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchHeterograftsAdenocarcinomaFemaleNeoplasm GradingCarcinogenesisResearch Article
researchProduct

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach

2021

(1) Background: Prostate-specific membrane antigen (PSMA) has been extensively studied in the last decade. It became a promising biological target in the diagnosis and therapy of PSMA-expressing cancer diseases. Although there are several radiolabeled PSMA inhibitors available, the search for new compounds with improved pharmacokinetic properties and simplified synthesis is still ongoing. In this study, we developed PSMA ligands with two different hybrid chelators and a modified linker. Both compounds have displayed a promising pharmacokinetic profile. (2) Methods: DATA5m.SA.KuE and AAZTA5.SA.KuE were synthesized. DATA5m.SA.KuE was labeled with gallium-68 and radiochemical yields of various…

Diagnostic ImagingGlutamate Carboxypeptidase IIBiodistributionmedia_common.quotation_subjectPharmaceutical ScienceOrganic chemistryChemistry Techniques Syntheticurologic and male genital diseasesArticleAnalytical ChemistryTranslational Research BiomedicalMicechemistry.chemical_compoundhybrid chelatorNude mouseQD241-441In vivoNeoplasmsDrug DiscoveryLNCaPAnimalsHumansChelationradionuclide diagnosis and therapyPhysical and Theoretical ChemistryInternalizationChelating Agentsmedia_commonMolecular StructurebiologyChemistryRadiochemistrybiology.organism_classificationDisease Models AnimalKineticsChemistry (miscellaneous)Isotope LabelingAntigens SurfaceHeterograftsMolecular MedicineRadiopharmaceuticalsAmmonium acetateEx vivoprostate specific membrane antigen PSMAProtein BindingMolecules
researchProduct

High-Temperature Sintering of Xenogeneic Bone Substitutes Leads to Increased Multinucleated Giant Cell Formation: In Vivo and Preliminary Clinical Re…

2014

The present preclinical and clinical study assessed the inflammatory response to a high-temperature–treated xenogeneic material (Bego-Oss) and the effects of this material on the occurrence of multinucleated giant cells, implantation bed vascularization, and regenerative potential. After evaluation of the material characteristics via scanning electron microscopy, subcutaneous implantation in CD-1 mice was used to assess the inflammatory response to the material for up to 60 days. The clinical aspects of this study involved the use of human bone specimens 6 months after sinus augmentation. Established histologic and histomorphometric analysis methods were applied. After implantation, the mat…

Giant Cells Foreign-BodyInflammationPathologymedicine.medical_specialtyHot TemperatureAngiogenesisChemistryTemperatureBiomaterialHuman boneAnatomyGiant CellsClinical studyMiceGiant cellIn vivoBone SubstitutesSubcutaneous implantationmedicineAnimalsHeterograftsHumansOral SurgeryHigh heatThe Journal of oral implantology
researchProduct

Tissue engineered pre-vascularized buccal mucosa equivalents utilizing a primary triculture of epithelial cells, endothelial cells and fibroblasts

2015

Artificial generated buccal mucosa equivalents are a promising approach for the reconstruction of urethral defects. Limiting in this approach is a poor blood vessel supply after transplantation, resulting in increased morbidity and necrosis. We generated a pre-vascularized buccal mucosa equivalent in a tri-culture of primary buccal epithelial cells, fibroblasts and microvascular endothelial cells, using a native collagen membrane as a scaffold. A successful pre-vascularization and dense formation of capillary-like structures at superficial areas was demonstrated. The lumen size of pre-formed blood vessels corresponded to the capillary size in vivo (10-30 μm). Comparing native with a highly …

Male0301 basic medicinePathologymedicine.medical_specialtyNecrosisForeskinGingivaBiophysicsMice NudeTransplantsBioengineeringBiologyBiomaterialsAngiopoietinMice03 medical and health sciencesForeskinTissue engineeringmedicineAnimalsHumansSecretionCells CulturedTissue EngineeringTissue ScaffoldsMouth MucosaEndothelial CellsEpithelial CellsMembranes ArtificialBuccal administrationFibroblastsCoculture TechniquesCapillariesOrganoidsPlatelet Endothelial Cell Adhesion Molecule-1Transplantation030104 developmental biologymedicine.anatomical_structureMechanics of MaterialsCeramics and CompositesHeterograftsAngiogenesis Inducing AgentsCollagenmedicine.symptomBlood vesselBiomaterials
researchProduct

Balancing Passive and Active Targeting to Different Tumor Compartments Using Riboflavin-Functionalized Polymeric Nanocarriers

2017

Riboflavin transporters (RFTs) and the riboflavin carrier protein (RCP) are highly upregulated in many tumor cells, tumor stem cells, and tumor neovasculature, which makes them attractive targets for nanomedicines. Addressing cells in different tumor compartments requires drug carriers, which are not only able to accumulate via the EPR effect but also to extravasate, target specific cell populations, and get internalized by cells. Reasoning that antibodies are among the most efficient targeting systems developed by nature, we consider their size (-10-15 nm) to be ideal for balancing passive and active tumor targeting. Therefore, small, short-circulating (10 kDa, -7 nm, t1/2 - 1 h) and large…

MaleBiodistributionMaterials scienceCell SurvivalPolymersSurface PropertiesRiboflavinBioengineering02 engineering and technology010402 general chemistry01 natural sciencesPolyethylene GlycolsMiceProstate cancerDownregulation and upregulationRiboflavin-carrier proteinCell Line TumorPEG ratiomedicineAnimalsHumansTissue DistributionGeneral Materials ScienceParticle Sizepassive and active tumor targetingCell ProliferationDrug CarriersbiologyMechanical EngineeringMembrane Transport ProteinsProstatic NeoplasmsTransporterGeneral Chemistry021001 nanoscience & nanotechnologyCondensed Matter Physicsmedicine.diseasen/a OA procedure0104 chemical sciencesCell biologybranched PEGBiochemistrybiology.proteinHeterograftsAntibody0210 nano-technologyDrug carrierNano Letters
researchProduct

Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent surviva…

2014

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by the Bcr-Abl oncoprotein with constitutive tyrosine kinase activity. Exosomes are nanovesicles released by cancer cells that are involved in cell-to-cell communication thus potentially affecting cancer progression. It is well known that bone marrow stromal microenvironment contributes to disease progression through the establishment of a bi-directional crosstalk with cancer cells. Our hypothesis is that exosomes could have a functional role in this crosstalk. Interleukin-8 (IL 8) is a proinflammatory chemokine that activates multiple signalling pathways downstream of two receptors (CXCR1 and CXCR2). We demon…

MaleCancer ResearchChemokineStromal cellCell SurvivalMice SCIDExosomesChronic myelogenous leukemia Bone marrow stromal cells Tumour microenvironment Exosomes Interleukin 8ExosomeMiceCell MovementMice Inbred NODSettore BIO/13 - Biologia ApplicataCell Line TumorLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesParacrine CommunicationCell AdhesionTumor MicroenvironmentmedicineAnimalsHumansCXC chemokine receptorsStem Cell NichebiologyInterleukin-8Mesenchymal Stem Cellsmedicine.diseaseUp-RegulationLeukemiaPhenotypemedicine.anatomical_structureOncologyCancer cellImmunologyCancer researchbiology.proteinHeterograftsBone marrowSignal TransductionChronic myelogenous leukemiaCancer Letters
researchProduct

Outcomes of complex femorodistal sequential autologous vein and biologic prosthesis composite bypass grafts

2014

Objective Femorodistal autologous vein bypass proves to be the preferred surgical therapy for long arterial occlusions and provides excellent early and long-term results in critical lower limb ischemia. Whenever vein length was insufficient and two distal outflow arteries were present, a sequential composite bypass configuration was chosen with human umbilical vein (HUV) or ovine collagen prosthesis (Omniflow II; Bio Nova International Pty Ltd, North Melbourne, Australia) as the proximal prosthetic part of the bypass. Single-center experience with this technique regarding limb salvage, graft function, secondary reinterventions, and biodegeneration is presented. Methods Between January 1998 …

MaleUmbilical Veinsmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentIschemiaProsthesis DesignProsthesisBlood Vessel Prosthesis ImplantationPeripheral Arterial DiseaseRisk FactorsBlood vessel prosthesismedicineAnimalsHumansVascular PatencyAutograftsVascular PatencyAgedRetrospective StudiesAged 80 and overBioprosthesisUltrasonography Doppler DuplexSheepmedicine.diagnostic_testbusiness.industryRetrospective cohort studyMiddle AgedLimb Salvagemedicine.diseaseThrombosisBlood Vessel ProsthesisSurgeryFemoral ArteryRadiographyTreatment OutcomeAngiographyHeterograftsFemaleSurgerymedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessJournal of Vascular Surgery
researchProduct

The Role of Immunohistochemistry in Rhabdomyosarcoma Diagnosis Using Tissue Microarray Technology and a Xenograft Model

2015

Rhabdomyosarcomas (RMS) may resemble other non-myogenic sarcomas and malignant rhabdoid tumor (MRT). Alveolar rhabdomyosarcoma (ARMS) often harbors a typical translocation, but embryonal rhabdomyosarcoma (ERMS) lacks any specific rearrangement. Histopathology is not always sufficient for an unequivocal diagnosis, necessitating ancillary studies, including immunohistochemistry (IHC). Sixteen genetically tested RMS and two MRT were xenografted and followed in successive passages. Tissue microarrays were constructed including samples from original and xenograft tumors. Desmin, myogenin, CK, EMA, INI1, LSD1, AP2 beta, fibrillin-2, HMGA2, nestin, and SIRT1 were tested using immunohistochemical s…

Malemusculoskeletal diseasesmedicine.medical_specialtyPathologygenetic structuresMice NudeBiologyPathology and Forensic MedicineDiagnosis DifferentialMiceRhabdomyosarcomaBiomarkers TumormedicineAnimalsHumansRhabdomyosarcomaRhabdoid TumorTissue microarraytissue microarraysGeneral MedicineNestinmedicine.diseasemusculoskeletal systemImmunohistochemistryDisease Models AnimalxenograftsTissue Array AnalysisPediatrics Perinatology and Child HealthimmunohistochemistryAlveolar rhabdomyosarcomaCancer researchHeterograftsImmunohistochemistryHistopathologyDesminEmbryonal rhabdomyosarcomarhabdomyosarcoma
researchProduct

SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia

2014

SIRT1 is an important regulator of cellular stress response and genomic integrity. Its role in tumorigenesis is controversial. Whereas sirtuin 1 (SIRT1) can act as a tumor suppressor in some solid tumors, increased expression has been demonstrated in many cancers, including hematologic malignancies. In chronic myeloid leukemia, SIRT1 promoted leukemia development, and targeting SIRT1 sensitized chronic myeloid leukemia progenitors to tyrosine kinase inhibitor treatment. In this study, we investigated the role of SIRT1 in acute myeloid leukemia (AML). We show that SIRT1 protein, but not RNA levels, is overexpressed in AML samples harboring activating mutations in signaling pathways. In FMS-l…

Myeloidendocrine system diseasesmedicine.drug_classImmunologyBiologymedicine.disease_causeBiochemistryTyrosine-kinase inhibitorMiceSirtuin 1hemic and lymphatic diseasesmedicineAnimalsHumansGene Knock-In TechniquesKinase activityfood and beveragesMyeloid leukemiaCell BiologyHematologymedicine.diseaseEnzyme ActivationMice Inbred C57BLLeukemia Myeloid Acuteenzymes and coenzymes (carbohydrates)Leukemiamedicine.anatomical_structureGene Knockdown TechniquesCancer researchHeterograftsTumor Suppressor Protein p53Signal transductionCarcinogenesisTyrosine kinasehormones hormone substitutes and hormone antagonistsDNA DamageSignal TransductionBlood
researchProduct